These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 15991644)

  • 1. [Efavirenz].
    Taéron C
    Rev Infirm; 2005 May; (111):37-8. PubMed ID: 15991644
    [No Abstract]   [Full Text] [Related]  

  • 2. A review of abacavir and efavirenz: new antiretroviral drugs to treat HIV-1 infection.
    Wolbach J; Capoccia K
    Nurse Pract; 1999 Jun; 24(6):81-2, 87-90, 92. PubMed ID: 10431297
    [No Abstract]   [Full Text] [Related]  

  • 3. Manic syndrome associated with efavirenz overdose.
    Blanch J; Corbella B; García F; Parellada E; Gatell JM
    Clin Infect Dis; 2001 Jul; 33(2):270-1. PubMed ID: 11418896
    [No Abstract]   [Full Text] [Related]  

  • 4. Switching from protease inhibitors to the non-nuke efavirenz.
    TreatmentUpdate; 2001; 12(12):3. PubMed ID: 11570089
    [No Abstract]   [Full Text] [Related]  

  • 5. [Results of the AIDS-In-Europe Study. Non-nucleoside reverse transcriptase inhibitor does not equal non-nucleoside reverse transcriptase inhibitor].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():39. PubMed ID: 11373776
    [No Abstract]   [Full Text] [Related]  

  • 6. Four-drug regimens may be better.
    AIDS Patient Care STDS; 2000 Dec; 14(12):671. PubMed ID: 11119435
    [No Abstract]   [Full Text] [Related]  

  • 7. [The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection].
    van Leth F; Lange JM
    Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1719-22. PubMed ID: 16924943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efavirenz-induced catatonia.
    Sabato S; Wesselingh S; Fuller A; Ray J; Mijch A
    AIDS; 2002 Sep; 16(13):1841-2. PubMed ID: 12218403
    [No Abstract]   [Full Text] [Related]  

  • 9. [Didanosine--stability as backbone drug].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():83-4. PubMed ID: 16385888
    [No Abstract]   [Full Text] [Related]  

  • 10. [Efavirenz--comprehensive status of studies].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():79-81. PubMed ID: 16385886
    [No Abstract]   [Full Text] [Related]  

  • 11. Efavirenz-induced photoallergic dermatitis in HIV.
    Treudler R; Husak R; Raisova M; Orfanos CE; Tebbe B
    AIDS; 2001 May; 15(8):1085-6. PubMed ID: 11400003
    [No Abstract]   [Full Text] [Related]  

  • 12. Efavirenz-associated breast hypertrophy in HIV-infection patients.
    Mercié P; Viallard JF; Thiébaut R; Faure I; Rispal P; Leng B; Pellegrin JL
    AIDS; 2001 Jan; 15(1):126-9. PubMed ID: 11192857
    [No Abstract]   [Full Text] [Related]  

  • 13. Non-nucleoside reverse transcriptase inhibitors--an overview.
    Bell C; Matthews GV; Nelson MR
    Int J STD AIDS; 2003 Feb; 14(2):71-7. PubMed ID: 12662384
    [No Abstract]   [Full Text] [Related]  

  • 14. NNRTI hepatotoxicity: efavirenz versus nevirapine.
    Pulido F; Torralba M
    J HIV Ther; 2002 Nov; 7 Suppl 2():S3-16. PubMed ID: 12735215
    [No Abstract]   [Full Text] [Related]  

  • 15. Gynecomastia without lipodystrophy syndrome in HIV-infected men treated with efavirenz.
    Caso JA; Prieto Jde M; Casas E; Sanz J
    AIDS; 2001 Jul; 15(11):1447-8. PubMed ID: 11504970
    [No Abstract]   [Full Text] [Related]  

  • 16. [Valuable combination partner. Great benefit for therapy naive patients].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():82-4. PubMed ID: 15373061
    [No Abstract]   [Full Text] [Related]  

  • 17. Factors affecting adherence and convenience in antiretroviral therapy.
    Lafeuillade A
    Int J STD AIDS; 2001 Nov; 12 Suppl 4():18-24. PubMed ID: 11589824
    [No Abstract]   [Full Text] [Related]  

  • 18. [Protease inhibitor saving alternatives].
    MMW Fortschr Med; 2000 Mar; 142 Suppl 1():16-7. PubMed ID: 10863305
    [No Abstract]   [Full Text] [Related]  

  • 19. Efavirenz + emtricitabine + tenofovir: new combination. HIV infection: do not modify ongoing therapy just to use one less tablet. Better adherence than with separate dosing has not been demonstrated, while reduced efficacy is plausible.
    Prescrire Int; 2009 Jun; 18(101):105. PubMed ID: 19637416
    [No Abstract]   [Full Text] [Related]  

  • 20. Efavirenz (Sustiva).
    Res Initiat Treat Action; 2000 Mar; 6(1):22-3. PubMed ID: 11708181
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.